A Phase I/II Study of the EGF Vaccine CIMAvax in Combination With the Anti-PD1 Nivolumab in Patients With Previously Treated Advanced NSCLC
Phase of Trial: Phase I/II
Latest Information Update: 14 Jul 2017
At a glance
- Drugs BV NSCLC 001 (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 01 May 2017 Planned number of patients changed from 90 to 136.
- 23 Dec 2016 Status changed from not yet recruiting to recruiting.
- 02 Dec 2016 Planned number of patients changed from 136 to 90.